David Brassat
Overview
Explore the profile of David Brassat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
3043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benkert P, Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez J, et al.
Ann Neurol
. 2024 Oct;
PMID: 39411917
Objective: To investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B-cell depleting therapy...
2.
Hatchwell E, Smith 3rd E, Jalilzadeh S, Bruno C, Taoufik Y, Hendel-Chavez H, et al.
Front Neurol
. 2023 Jan;
13:1016377.
PMID: 36588876
Background: Progressive multifocal leukoencephalopathy (PML) is a rare and often lethal brain disorder caused by the common, typically benign polyomavirus 2, also known as JC virus (JCV). In a small...
3.
Schneider-Hohendorf T, Gerdes L, Pignolet B, Gittelman R, Ostkamp P, Rubelt F, et al.
J Exp Med
. 2022 Oct;
219(11).
PMID: 36305889
No abstract available.
4.
Schneider-Hohendorf T, Gerdes L, Pignolet B, Gittelman R, Ostkamp P, Rubelt F, et al.
J Exp Med
. 2022 Sep;
219(11).
PMID: 36048016
Epstein-Barr virus (EBV) infection precedes multiple sclerosis (MS) pathology and cross-reactive antibodies might link EBV infection to CNS autoimmunity. As an altered anti-EBV T cell reaction was suggested in MS,...
5.
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
Fissolo N, Pignolet B, Rio J, Vermersch P, Ruet A, deSeze J, et al.
Neurol Neuroimmunol Neuroinflamm
. 2021 Apr;
8(4).
PMID: 33903203
Objectives: The study aimed to assess the potential for serum neurofilament light chain (NFL) levels to predict the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab (NTZ)-treated patients with multiple...
6.
Ostkamp P, Salmen A, Pignolet B, Gorlich D, Andlauer T, Schulte-Mecklenbeck A, et al.
Proc Natl Acad Sci U S A
. 2020 Dec;
118(1).
PMID: 33376202
Multiple sclerosis (MS) disease risk is associated with reduced sun-exposure. This study assessed the relationship between measures of sun exposure (vitamin D [vitD], latitude) and MS severity in the setting...
7.
Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, et al.
Mult Scler
. 2020 Dec;
27(9):1458-1463.
PMID: 33269975
Background: Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy. Objective: To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate...
8.
Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud D, Wiertlewski S, et al.
Mult Scler
. 2020 Oct;
27(10):1556-1563.
PMID: 33124504
Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS). Objective: The aim of this study was to compare the effectiveness between natalizumab (NTZ) and...
9.
Schwab N, Schneider-Hohendorf T, Pignolet B, Brassat D, Wiendl H
Neurology
. 2020 Sep;
95(11):505.
PMID: 32934158
No abstract available.
10.
Longbrake E, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, et al.
Mult Scler
. 2020 Jul;
27(6):883-894.
PMID: 32716690
Background: Delayed-release dimethyl fumarate (DMF) demonstrates sustained efficacy and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially, then stabilizes on treatment. Objective: PROCLAIM, a 96-week,...